Alpha DNA Investment Management LLC Has $1.91 Million Stock Holdings in Colgate-Palmolive (NYSE:CL)

Alpha DNA Investment Management LLC raised its stake in shares of Colgate-Palmolive (NYSE:CL) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,058 shares of the company’s stock after purchasing an additional 274 shares during the quarter. Colgate-Palmolive accounts for 0.7% of Alpha DNA Investment Management LLC’s portfolio, making the stock its 24th largest holding. Alpha DNA Investment Management LLC’s holdings in Colgate-Palmolive were worth $1,914,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Barclays PLC boosted its stake in Colgate-Palmolive by 38.7% in the 3rd quarter. Barclays PLC now owns 7,644,189 shares of the company’s stock valued at $793,542,000 after buying an additional 2,132,747 shares in the last quarter. M&T Bank Corp lifted its holdings in shares of Colgate-Palmolive by 8.2% during the third quarter. M&T Bank Corp now owns 288,050 shares of the company’s stock valued at $29,903,000 after acquiring an additional 21,862 shares during the period. Te Ahumairangi Investment Management Ltd boosted its stake in shares of Colgate-Palmolive by 2.5% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 43,957 shares of the company’s stock valued at $4,537,000 after purchasing an additional 1,060 shares in the last quarter. Chelsea Counsel Co. grew its holdings in shares of Colgate-Palmolive by 10.0% in the 3rd quarter. Chelsea Counsel Co. now owns 5,500 shares of the company’s stock worth $571,000 after purchasing an additional 500 shares during the last quarter. Finally, Fulcrum Equity Management grew its holdings in shares of Colgate-Palmolive by 3.0% in the 3rd quarter. Fulcrum Equity Management now owns 5,280 shares of the company’s stock worth $548,000 after purchasing an additional 153 shares during the last quarter. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Stock Performance

CL stock opened at $95.49 on Friday. Colgate-Palmolive has a twelve month low of $85.32 and a twelve month high of $109.30. The company has a quick ratio of 0.58, a current ratio of 0.92 and a debt-to-equity ratio of 13.40. The company has a market cap of $77.45 billion, a P/E ratio of 27.13, a price-to-earnings-growth ratio of 4.20 and a beta of 0.40. The business’s fifty day moving average is $91.15 and its 200-day moving average is $92.48.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, January 31st. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.01. Colgate-Palmolive had a return on equity of 477.77% and a net margin of 14.38%. During the same period last year, the business earned $0.87 EPS. Equities research analysts forecast that Colgate-Palmolive will post 3.75 EPS for the current year.

Colgate-Palmolive declared that its Board of Directors has initiated a stock repurchase plan on Thursday, March 20th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its shares are undervalued.

Colgate-Palmolive Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Thursday, April 17th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, April 17th. This represents a $2.08 dividend on an annualized basis and a yield of 2.18%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.50. Colgate-Palmolive’s payout ratio is currently 59.09%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Barclays dropped their price objective on shares of Colgate-Palmolive from $89.00 to $86.00 and set an “equal weight” rating for the company in a report on Friday, April 11th. TD Cowen dropped their price target on Colgate-Palmolive from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Wells Fargo & Company boosted their price objective on Colgate-Palmolive from $83.00 to $88.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 2nd. Piper Sandler decreased their target price on Colgate-Palmolive from $108.00 to $107.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. Finally, JPMorgan Chase & Co. cut their price target on Colgate-Palmolive from $99.00 to $95.00 and set an “overweight” rating for the company in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $102.17.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.